• International trade and protection of intellectual property; TRIPS Waiver; global supply chain issues, including the Medical Supply Chain Resiliency Act; compulsory licensing and other IP issues in multiple countries.
• Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 and other viral pathogens, including: manufacturing, clinical trials, reimbursement and coverage.
• Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
• Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.
• Funding for and policies relating to Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
• Legislative and regulatory proposals to change international and domestic corporate tax law and policy.

Duration: January 1, 2008 to present

General Issues: Trade (Domestic & Foreign), Health Issues, Medicare/Medicaid, Copyright/Patent/Trademark, Budget/Appropriations, Taxation/Internal Revenue Code, Veterans, Immigration, Indian/Native American Affairs, Defense, Foreign Relations, Pharmacy, Law Enforcement/Crime/Criminal Justice, Science/Technology

Spending: about $64,702,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2008: U.S. Senate, House of Representatives, U.S. Trade Representative (USTR), Commerce - Dept of (DOC), State - Dept of (DOS), Health & Human Services - Dept of (HHS), Patent & Trademark Office (PTO), Natl Security Council (NSC), White House Office, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), Office of the Vice President of the United States, Food & Drug Administration (FDA), Office of Management & Budget (OMB), Treasury - Dept of, Natl Economic Council (NEC), Veterans Affairs - Dept of (VA), U.S. Agency for International Development (USAID), Commerce - Dept of (DOC), Health & Human Services - Dept of (HHS), Defense - Dept of (DOD), Executive Office of the President (EOP), Indian Health Service, Executive Office of the President (EOP),, Defense - Dept of (DOD), Veterans Affairs - Dept of (VA),, Office of Science & Technology Policy (OSTP), Commerce - Dept of (DOC),, Health & Human Services - Dept of (HHS),